» Go to news main
Just published! Lutathera® lutetium (177lu) oxodotreotide for neuroendocrine tumours: a game changer concept in cancer treatment
Posted by Angie Kinsman on
June 30, 2022
in
Nuclear Medicine
Dr. Steven Burrell has published a new article in Le Patient Magazine!
Lutathera® lutetium (177lu) oxodotreotide for neuroendocrine tumours: a game changer concept in cancer treatment
Steven Burrell, MD, FRCPC Head of Nuclear Medicine QEII Health Sciences Centre
"When cancer has spread within the body the 2 main pillars of treatment are drugs such as chemotherapy which are administered internally and distribute throughout the body, and radiation which delivers tumour-destroying radiation from outside the body. However there is another approach..." Read more.
Recent News
- Just published! No difference in cerebral perfusion between the wild‑type and the 5XFAD mouse model of Alzheimer’s disease
- Just published! Canadian Stroke Best Practice Recommendations: Acute Stroke Management, 7th Edition Practice Guidelines Update, 2022
- Physician Leadership Workshop for Women in Radiology
- ICRE
- Just published! Intra‑individual comparison of 18F‑sodium fluoride PET–CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC‑A1): a multicentre, phase 3 trial
- Just published! Surgical or Endovascular Treatment of MCA Aneurysms: An Agreement Study
- Just published! Endovascular thrombectomy and intravenous alteplase in patients with acute ischemic stroke due to large vessel occlusion: A clinical practice guideline
- Just published! Preparedness of Residents and Medical Students for the Transition to Competence by Design in Diagnostic Radiology Post‑Graduate Medical Education
Comments
All comments require a name and email address. You may also choose to log-in using your preferred social network or register with Disqus, the software we use for our commenting system. Join the conversation, but keep it clean, stay on the topic and be brief.
Read comments policy.
comments powered by Disqus